Minimize Uncertainty – Make Informed Decisions – Succeed

Lucid Diligence Brief - Tech

Lucid Diligence Brief: Neuralink’s 2026 high-volume BCI plan

January 3, 2026digital health,clinical trials,reimbursement,Regulatory,NeuroTech,biopharma,BCI,Lucid Diligence Brief,payer access,manufacturing scalesurgical robotics

Lucid Diligence Brief: Neuralink’s 2026 high-volume BCI plan Professional…

by Timos Papagatsias

Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Transcenta x EirGenix HiCB licensing

January 2, 2026biosimilars,biopharma,Lucid Diligence Brief,payer access,diligence,CDMO,continuous bioprocessing,manufacturing technology,Asia biotech,process validationHKEX

Lucid Diligence Brief: Transcenta x EirGenix HiCB licensing Professional…

by Timos Papagatsias

Public_Health

Public Health 2025 Review: Prevention Under Pressure and Signals Too Loud to Ignore

January 2, 2026Digital health transformation,Public health funding,real-world evidence,Global health landscape,BioPharma and Tech News,Public Health News,Regulatory catalysts,Market access strategy,vaccine policy,Public health market trends,Healthcare policy trends,Global health strategy,Population health management,Health systems innovation,Epidemiology insightsInfectious disease preparedness,Health equity initiatives

In 2025, public health entered a paradoxical phase: unprecedented scientific…

by LucidQuest

Lucid Diligence Brief - Tech

Lucid Diligence Brief: DP Technology Series C for AI-for-Science initiative

January 1, 2026biopharma,Lucid Diligence Brief,diligence,AI for Science,deep tech,China venture,R&D platforms,scientific computing,lab automation,enterprise AImaterials science

Lucid Diligence Brief: DP Technology Series C for AI-for-Science initiative…

by Timos Papagatsias

Cardiovascular

Cardiovascular 2025 Review: From late rescue to earlier, smarter intervention

January 1, 2026Lipid management innovation,FDA cardiovascular approvals,precision medicine,Global cardiovascular market,BioPharma and Tech News,Cardiovascular News,AI in cardiology,Pharma industry trends,Biopharma investment,Pharma pipeline analysis,Regulatory catalysts,Cardiovascular market trends,Cardiovascular drug pipeline,Cardiovascular strategy,Heart failure therapiesAtherosclerosis treatments,Cardio-metabolic disease

In 2025, cardiovascular medicine pivoted decisively toward earlier…

by LucidQuest

Rare Disease news

Rare Disease 2025 Review: From Orphan Innovation to a System-Level Stress Test

January 1, 2026Ultra-rare diseases,FDA orphan drug approvals,precision medicine,Global rare disease market,BioPharma and Tech News,RNA therapeutics,Rare Disease News,Pharma industry trends,Biopharma investment,Pharma pipeline analysis,Regulatory catalysts,Market access strategy,Specialty pharma,Rare disease market trends,Rare disease drug pipelineOrphan drug development,Gene therapy innovation

In 2025, rare disease innovation accelerated faster than the systems designed…

by LucidQuest

Lucid Diligence Brief - Tech

Lucid Diligence Brief: Sinopia Biosciences receives NIGMS grant for LEADS platform

December 31, 2025digital health,drug discovery,AI in healthcare,Parkinson's Disease,biopharma,Lucid Diligence Brief,diligence,platform biotech,metabolomics,NIH SBIR,grantsnon-dilutive funding

Lucid Diligence Brief: Sinopia Biosciences receives NIGMS grant for LEADS…

by Timos Papagatsias

Immunology

Immunology 2025 Review: From Mechanism Proliferation to Platform Discipline

December 31, 2025FDA immunology approvals,Global immunology market,precision medicine,Specialty pharma,BioPharma and Tech News,Immunology News,Pharma industry trends,Biopharma investment,Pharma pipeline analysis,Regulatory catalysts,Market access strategy,Immunology market trends,Immunology drug pipeline,Immunology strategy,Autoimmune disease therapiesInflammatory disease drugs,Biologic therapies

In 2025, immunology moved from breadth to discipline: sharper focus on…

by LucidQuest

Endocrinology

Endocrinology 2025 Review: Outcomes, Access, and Earlier Intervention

December 30, 2025GLP-1 innovation,FDA endocrinology approvals,precision medicine,Global endocrinology market,BioPharma and Tech News,obesity therapeutics,Endocrinology News,Pharma industry trends,Biopharma investment,Pharma pipeline analysis,Regulatory catalysts,Endocrinology market trends,Endocrinology drug pipeline,Endocrinology strategy,Metabolic disease therapiesHormone disorder treatments,Diabetes drug development

In 2025, endocrinology moved decisively toward outcomes that change long-term…

by LucidQuest

Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Johnson & Johnson acquires Halda Therapeutics

December 30, 2025Oncology,clinical trials,Regulatory,prostate cancer,biopharma,mCRPC,Lucid Diligence Brief,payer access,diligence,M&Ainduced proximity

Lucid Diligence Brief: Johnson & Johnson acquires Halda Therapeutics…

by Timos Papagatsias

Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Rectify and Boehringer Ingelheim partnership in CKD

December 29, 2025clinical trials,chronic kidney disease,nephrology,biopharma,Lucid Diligence Brief,payer access,diligence,partnerships,cardio-renal,CKD pipelinecalcification biology

Lucid Diligence Brief: Rectify and Boehringer Ingelheim partnership in CKD…

by Timos Papagatsias

Artificial_Intelligence

Artificial Intelligence in Healthcare 2025 Review: From Pilot Tools to Operating Infrastructure

December 29, 2025AI Governance,Population Health,digital health,Healthcare Technology Trends,pharma strategy,Healthcare Innovation,BioPharma and Tech News,healthcare AI,AI diagnostics,AI in Healthcare and Digital Health,Artificial Intelligence in Healthcare,clinical workflows,Clinical Decision-Making,Medical AI Regulation,Drug Development InnovationHealth Systems Transformation,Healthcare Policy

2025 marked the year artificial intelligence stopped behaving like an…

by LucidQuest

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required
You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.